Cargando…

Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands

INTRODUCTION: To improve therapeutic decision making, it is crucial that information regarding adverse drug reactions reaches patients. It is not enough to disseminate such findings through regulatory and scientific channels; targeted efforts to reach patients are necessary. One possible avenue is t...

Descripción completa

Detalles Bibliográficos
Autores principales: Härmark, Linda, Weits, Gerda, Meijer, Rietje, Santoro, Federica, Norén, G. Niklas, van Hunsel, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395903/
https://www.ncbi.nlm.nih.gov/pubmed/32418193
http://dx.doi.org/10.1007/s40264-020-00932-5
_version_ 1783565479064895488
author Härmark, Linda
Weits, Gerda
Meijer, Rietje
Santoro, Federica
Norén, G. Niklas
van Hunsel, Florence
author_facet Härmark, Linda
Weits, Gerda
Meijer, Rietje
Santoro, Federica
Norén, G. Niklas
van Hunsel, Florence
author_sort Härmark, Linda
collection PubMed
description INTRODUCTION: To improve therapeutic decision making, it is crucial that information regarding adverse drug reactions reaches patients. It is not enough to disseminate such findings through regulatory and scientific channels; targeted efforts to reach patients are necessary. One possible avenue is to collaborate with patient organizations. OBJECTIVES: The aim of this pilot study was to explore how adverse drug reactions can be communicated through patient organizations. METHODS: A text describing a signal of levothyroxine and panic attacks was tailored to patients’ needs, in terms of language, style and content, with emphasis placed on what to do when experiencing the symptoms described. The signal was communicated via the Dutch thyroid organization’s digital newsletter, social media channels, website and print magazine. RESULTS: The digital newsletter was distributed to around 5000 subscribers. On Facebook, 13,820 people viewed the message, with 2346 clicks in the message, indicating an intention to read the whole post. The interactions on social media were positive, and the tone was respectful. CONCLUSION: Patient organizations can help enable effective communication of adverse drug reactions to a relevant audience. The social media post generated more engagement than other communications from the patient organization, indicating a strong interest in this information. The additional patient experiences that were shared in the comments on social media further strengthened the original signal and its relevance to patients, creating an interesting feedback loop. The favourable experiences in this study support further consideration and exploration of this approach to communicate adverse drug reactions to patients.
format Online
Article
Text
id pubmed-7395903
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-73959032020-08-13 Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands Härmark, Linda Weits, Gerda Meijer, Rietje Santoro, Federica Norén, G. Niklas van Hunsel, Florence Drug Saf Original Research Article INTRODUCTION: To improve therapeutic decision making, it is crucial that information regarding adverse drug reactions reaches patients. It is not enough to disseminate such findings through regulatory and scientific channels; targeted efforts to reach patients are necessary. One possible avenue is to collaborate with patient organizations. OBJECTIVES: The aim of this pilot study was to explore how adverse drug reactions can be communicated through patient organizations. METHODS: A text describing a signal of levothyroxine and panic attacks was tailored to patients’ needs, in terms of language, style and content, with emphasis placed on what to do when experiencing the symptoms described. The signal was communicated via the Dutch thyroid organization’s digital newsletter, social media channels, website and print magazine. RESULTS: The digital newsletter was distributed to around 5000 subscribers. On Facebook, 13,820 people viewed the message, with 2346 clicks in the message, indicating an intention to read the whole post. The interactions on social media were positive, and the tone was respectful. CONCLUSION: Patient organizations can help enable effective communication of adverse drug reactions to a relevant audience. The social media post generated more engagement than other communications from the patient organization, indicating a strong interest in this information. The additional patient experiences that were shared in the comments on social media further strengthened the original signal and its relevance to patients, creating an interesting feedback loop. The favourable experiences in this study support further consideration and exploration of this approach to communicate adverse drug reactions to patients. Springer International Publishing 2020-05-16 2020 /pmc/articles/PMC7395903/ /pubmed/32418193 http://dx.doi.org/10.1007/s40264-020-00932-5 Text en © The Author(s) 2020, corrected publication 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research Article
Härmark, Linda
Weits, Gerda
Meijer, Rietje
Santoro, Federica
Norén, G. Niklas
van Hunsel, Florence
Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands
title Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands
title_full Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands
title_fullStr Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands
title_full_unstemmed Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands
title_short Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands
title_sort communicating adverse drug reaction insights through patient organizations: experiences from a pilot study in the netherlands
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395903/
https://www.ncbi.nlm.nih.gov/pubmed/32418193
http://dx.doi.org/10.1007/s40264-020-00932-5
work_keys_str_mv AT harmarklinda communicatingadversedrugreactioninsightsthroughpatientorganizationsexperiencesfromapilotstudyinthenetherlands
AT weitsgerda communicatingadversedrugreactioninsightsthroughpatientorganizationsexperiencesfromapilotstudyinthenetherlands
AT meijerrietje communicatingadversedrugreactioninsightsthroughpatientorganizationsexperiencesfromapilotstudyinthenetherlands
AT santorofederica communicatingadversedrugreactioninsightsthroughpatientorganizationsexperiencesfromapilotstudyinthenetherlands
AT norengniklas communicatingadversedrugreactioninsightsthroughpatientorganizationsexperiencesfromapilotstudyinthenetherlands
AT vanhunselflorence communicatingadversedrugreactioninsightsthroughpatientorganizationsexperiencesfromapilotstudyinthenetherlands